Mesenchymal stem cell (MSC) therapy has been widely studied for its immunomodulatory potential in ulcerative colitis. A recent study published in Biomedicine & Pharmacotherapy examines whether pre-conditioning MSCs with Lactobacillus sakei CVL-001 can enhance their therapeutic effects.
The researchers found that probiotic-primed MSCs showed increased secretion of interleukin-10 (IL-10), a cytokine crucial for reducing inflammation and maintaining immune homeostasis. This effect was linked to activation of the STAT3 signaling pathway. Additionally, primed MSCs influenced macrophage behavior, reducing pro-inflammatory cytokine production and promoting an M2 phenotype, which is associated with tissue repair and immune regulation.
Further experiments revealed that conditioned media from L. sakei-treated MSCs suppressed T-cell and splenocyte proliferation, suggesting enhanced immunosuppressive properties. In a DSS-induced colitis mouse model, administration of these primed MSCs led to improved recovery, reduced inflammation, and better survival outcomes compared to unmodified MSCs.
These findings suggest that probiotics may be a valuable tool in optimizing MSC-based therapies for ulcerative colitis. This research provides insight into a potential strategy for improving treatment outcomes in IBD management.
